Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
May 23 2024 - 4:00PM
Arvinas, Inc. (Nasdaq: ARVN) today announced that two abstracts,
including one for ARV-766 in prostate cancer and one for TACTIVE-K,
a Phase 1b/2 clinical trial with vepdegestrant, a novel
investigational oral PROteolysis Targeting Chimera (PROTAC®) ER
degrader, in combination with Pfizer’s atirmociclib (PF-07220060),
an investigational CDK4 inhibitor, were accepted for presentation
at the 2024 American Society of Clinical Oncology Annual Congress
held May 31 to June 4, 2024, in Chicago, IL.
Presentation details are as
follows:
Title: ARV-766, a PROteolysis
TArgeting Chimera (PROTAC) androgen receptor (AR) degrader, in
metastatic castration-resistant prostate cancer (mCRPC): initial
results of a phase 1/2 studyPresentation Type and Abstract
Number: Rapid Oral Abstract, 5011Date:
Monday, June 3, 2024Time: 1:15 p.m. — 2:45 p.m.
CDTCategory: Genitourinary Cancer—Prostate,
Testicular, and PenileTitle: TACTIVE-K: phase 1b/2
study of vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC)
estrogen receptor (ER) degrader, in combination with PF-07220060, a
cyclin-dependent kinase (CDK)4 inhibitor, in ER+/human epidermal
growth factor receptor 2 (HER2)- advanced breast
cancerPresentation Type and Abstract Number:
Trial-in-Progress (TiP) TPS1131, Poster 103bDate:
Sunday, June 2, 2024Time: 9:00 a.m. — 12:00 p.m.
CDTCategory: Session Type and Title: Poster
Session – Breast Cancer—Metastatic
Abstracts are now available via the official ASCO
Annual Congress website here.
About ARV-766ARV-766 is an
investigational, orally bioavailable PROTAC protein degrader
designed to selectively target and degrade the androgen receptor
(AR). Preclinically, ARV-766 has demonstrated activity in models of
wild type androgen receptor tumors in addition to tumors with AR
mutations or amplification, both common potential mechanisms of
resistance to currently available AR-targeted therapies.
In April 2024, Arvinas entered into a transaction
with Novartis that included an exclusive license agreement for the
worldwide development and commercialization of ARV-766. Closing of
the transaction is subject to customary closing conditions,
including the expiration or termination of the waiting period under
the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
About Vepdegestrant Vepdegestrant
is an investigational, orally bioavailable PROTAC protein degrader
designed to specifically target and degrade the estrogen receptor
(ER) for the treatment of patients with ER positive human epidermal
growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer.
Vepdegestrant is being developed as a potential monotherapy and as
part of combination therapy across multiple treatment settings for
ER+/HER2- metastatic breast cancer.
In July 2021, Arvinas announced a global
collaboration with Pfizer for the co-development and
co-commercialization of vepdegestrant; Arvinas and Pfizer share
worldwide development costs, commercialization expenses, and
profits.
The U.S. Food and Drug Administration (FDA) has
granted vepdegestrant Fast Track designation as a monotherapy in
the treatment of adults with ER+/HER2- locally advanced or
metastatic breast cancer previously treated with endocrine-based
therapy.
About ArvinasArvinas is a
clinical-stage biotechnology company dedicated to improving the
lives of patients suffering from debilitating and life-threatening
diseases through the discovery, development, and commercialization
of therapies that degrade disease-causing proteins. Arvinas uses
its proprietary PROTAC® Discovery Engine platform to engineer
proteolysis targeting chimeras, or PROTAC® targeted protein
degraders, that are designed to harness the body’s own natural
protein disposal system to selectively and efficiently degrade and
remove disease-causing proteins. In addition to its robust
preclinical pipeline of PROTAC protein degraders against validated
and “undruggable” targets, the company has four investigational
clinical-stage programs: vepdegestrant for the treatment of
patients with locally advanced or metastatic ER+/HER2- breast
cancer; ARV-766 and bavdegalutamide for the treatment of men with
metastatic castration-resistant prostate cancer; and ARV-102 for
the treatment of patients with neurodegenerative disorders. For
more information, visit www.arvinas.com.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995
that involve substantial risks and uncertainties, including
statements regarding plans with respect to ARV-766 and the closing
of the deal with Novartis. All statements, other than statements of
historical facts, contained in this press release, including
statements regarding Arvinas’ strategy, future operations, future
financial position, future revenues, projected costs, prospects,
plans and objectives of management, are forward-looking statements.
The words “anticipate,” “believe,” “estimate,” “expect,” “intend,”
“may,” “might,” “plan,” “predict,” “project,” “target,”
“potential,” “will,” “would,” “could,” “should,” “continue,” and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words.
Arvinas may not actually achieve the plans,
intentions or expectations disclosed in these forward-looking
statements, and you should not place undue reliance on such
forward-looking statements. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in
the forward-looking statements Arvinas makes as a result of various
risks and uncertainties, including but not limited to: whether the
closing conditions for the deal between Arvinas and Novartis will
be satisfied; whether Arvinas and Pfizer will be able to
successfully conduct and complete clinical development for, or will
be able to obtain marketing approval for and commercialize
vepdegestrant and its other product candidates on current timelines
or at all; Arvinas’ ability to protect its intellectual property
portfolio; whether Arvinas’ cash and cash equivalent resources will
be sufficient to fund its foreseeable and unforeseeable operating
expenses and capital expenditure requirements; and other important
factors discussed in the “Risk Factors” section of Arvinas’ Annual
Report on Form 10-K for the year ended December 31, 2023 and
subsequent other reports on file with the U.S. Securities and
Exchange Commission. The forward-looking statements contained in
this press release reflect Arvinas’ current views with respect to
future events, and Arvinas assumes no obligation to update any
forward-looking statements, except as required by applicable law.
These forward-looking statements should not be relied upon as
representing Arvinas’ views as of any date subsequent to the date
of this release.
Contacts
Investors:Jeff Boyle+1 (347)
247-5089Jeff.Boyle@arvinas.com
Media:Kathleen Murphy+1 (760)
622-3771Kathleen.Murphy@arvinas.com
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
From May 2024 to Jun 2024
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
From Jun 2023 to Jun 2024